FDA Grants Priority Review to Merck's Application for KEYTRUDA ® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom

7 months ago 30

1. Homepage
2. Finance
3. FDA Grants Priority Review to Merck's Application for KEYTRUDA ® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom